Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Medtronic
Johnson and Johnson
Harvard Business School
Dow

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

ARANESP Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ARANESP
Pharmacology for ARANESP
Ingredient-typeErythropoietin
Physiological EffectIncreased Erythroid Cell Production

US Patents for ARANESP

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing Bayer Intellectual Property GMBH (Monheim, DE) 2026-12-05 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing CHONG KUN DANG PHARMACEUTICAL CORP. (Seoul, KR) 2031-10-18 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK MEMORIAL SLOAN-KETTERING CANCER CENTER (New York, NY) 2034-12-23 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing Corning Incorporated (Corning, NY) 2037-10-23 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing 2030-02-02 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) 2029-05-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   See Pricing Bayer Intellectual Property GmbH (Monheim, DE) 2031-04-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for ARANESP

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300075 Netherlands   See Pricing PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
01C0050 France   See Pricing PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
SPC/GB01/055 United Kingdom   See Pricing PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
43/2001 Austria   See Pricing PRODUCT NAME: DARBEPOETIN-ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
SPC028/2001 Ireland   See Pricing SPC028/2001: 20031204, EXPIRES: 20160607
PA2004015 Lithuania   See Pricing PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
SZ 43/2001 Austria   See Pricing PRODUCT NAME: DARBEPOETIN-ALFA
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School
Medtronic
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.